Article · Wikipedia archive · Last revised Jul 2, 2026

PRC200-SS

PRC200-SS is an experimental drug of the triple reuptake inhibitor class that was investigated by the Mayo Clinic.

Last revised
Jul 2, 2026
Read time
≈ 1 min
Length
163 w
Citations
3
Source
Wikipedia ↗
PRC200-SS
Identifiers
  • (1S,2S)-3-(Methylamino)-2-naphthalen-2-yl-1-phenylpropan-1-ol
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.207.294
Chemical and physical data
FormulaC20H21NO
Molar mass291.394 g·mol−1
3D model (JSmol)
  • O[C@H](c1ccccc1)[C@H](CNC)c2cc3ccccc3cc2
  • InChI=1S/C20H21NO/c1-21-14-19(20(22)16-8-3-2-4-9-16)18-12-11-15-7-5-6-10-17(15)13-18/h2-13,19-22H,14H2,1H3/t19-,20-/m1/s1 ☒N
  • Key:RSZGIFQDUIROGN-WOJBJXKFSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

PRC200-SS is an experimental drug of the triple reuptake inhibitor class that was investigated by the Mayo Clinic.12

Preclinical toxicology studies of PRC200-SS in cynomolgus monkeys showed dose proportional kidney toxicity,3 precluding any further drug development.

References

References

  1. Liang Y, Shaw AM, Boules M, Briody S, Robinson J, Oliveros A, et al. (November 2008). "Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)". The Journal of Pharmacology and Experimental Therapeutics. 327 (2): 573–83. doi:10.1124/jpet.108.143610. PMID 18689611. S2CID 12635418.
  2. "Triple Reuptake Inhibitors for the Treatment of Depression". Mayo Clinic Ventures.
  3. Guha M, Heier A, Price S, Bielenstein M, Caccese RG, Heathcote DI, et al. (April 2011). "Assessment of biomarkers of drug-induced kidney injury in cynomolgus monkeys treated with a triple reuptake inhibitor". Toxicological Sciences. 120 (2): 269–83. doi:10.1093/toxsci/kfr013. PMID 21258088.